Lumefantrine
| Clinical data | |
|---|---|
| Other names | benflumetol |
| AHFS/Drugs.com | International Drug Names |
| MedlinePlus | a609024 |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 99.7% |
| Metabolites | desbutyl-lumefantrine |
| Elimination half-life | 3-6 days |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.133.797 |
| Chemical and physical data | |
| Formula | C30H32Cl3NO |
| Molar mass | 528.94 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 130 to 132 °C (266 to 270 °F) |
| Solubility in water | 30.9ng/mL |
| |
| |
| (what is this?) (verify) | |
Lumefantrine (or benflumetol) is an antimalarial drug. It is only used in combination with artemether. The term "co-artemether" is sometimes used to describe this combination. Lumefantrine has a much longer half-life compared to artemether (3-6 days vs. 2 hours), and is therefore thought to clear any residual parasites that remain after combination treatment.